Efficacy and safety of the folfox4 regimen versus doxorubicin in chinese patients with advanced hepatocellular carcinoma: A subgroup analysis of the each study

Oncologist

Volumn 19, Issue 11, 2014, Pages 1169-1178

  Qin, Shukui ^a   Cheng, Ying ^b   Liang, Jun ^c   Shen, Lin ^d   Bai, Yuxian ^e   Li, Jianfeng ^f   Fan, Jia ^g   Liang, Lijian ^h   Zhang, Yaqi ⁱ   Wu, Gang ^j   Rau, Kun Ming ^k   Yang, Tsai Shen ^k   Jian, Zhixiang ^l   Liang, Houjie ^m   Sun, Yan ⁿ  

^a Bayi Hospital   (China)

^b JILIN PROVINCIAL CANCER HOSPITAL   (China)

^c QINGDAO UNIVERSITY   (China)

^d PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^e Heilongjiang Province Hospital   (China)

^f Sanofi China ^*  (China)

^g ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^h THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

ⁱ SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^j UNION HOSPITAL   (China)

^k CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^l GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^m SOUTHWEST HOSPITAL   (China)

ⁿ CANCER HOSPITAL   (China)

more..

Author keywords

FOLFOX4 regimen; Hepatocellular carcinoma; Oxaliplatin; Systemic chemotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM; CREATININE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GLUCOSE; HEMOGLOBIN; OXALIPLATIN; POTASSIUM; SODIUM; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD CELL COUNT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CREATININE CLEARANCE; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ETHNICITY; FATIGUE; FEMALE; FEVER; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PHLEBITIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RESPIRATORY FAILURE; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TOXICITY TESTING; TREATMENT RESPONSE; VOMITING; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; CONTROLLED STUDY; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85047695412     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0190     Document Type: Article

References (52)

1. Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2012 v1.0,cancerincidenceand mortality worldwide:IARC CancerBaseNo.11.InternationalAgencyforResearch on Cancer; 2013. Available at http://globocan.iarc.fr. Accessed December 10, 2013.
2. Zhou JY, Zhang L, Li L et al. High hepatitis B virus load is associated with hepatocellular carcinomas development in Chinese chronic hepatitis B patients: A case control study. Virol J 2012;9:16.
3. Liang X, Bi S, Yang W et al. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009;27:6550–6557.
4. London WT, Evans AA, McGlynn K et al. Viral, host and environmental risk factors for hepato-cellular carcinoma: A prospective study in Hai-men City, China. Intervirology 1995;38:155-161.
5. Sun Z, Lu P, Gail MH et al. Increased risk of hepatocellular carcinomainmale hepatitisBsurface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hep-atology 1999;30:379–383.
6. Gao J, Xie L, Yang WS et al. Risk factors of hepatocellular carcinoma—current status and perspectives. Asian Pac J Cancer Prev 2012;13: 743–752.
7. Shi J, Zhu L, Liu S et al. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 2005;92:607-612.
8. Zhang H, Zhai Y, Hu Z et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010;42:755-758.
9. Li S, Qian J, Yang Y et al. GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers. PLoS Genet 2012;8:e1002791.
10. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology2011;53: 1020-1022.
11. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
12. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology 1999;30:1434-1440.
13. Pinter M, Hucke F, Graziadei I et al. Advanced-stage hepatocellular carcinoma: Transarterial che-moembolization versus sorafenib. Radiology 2012; 263:590-599.
14. Fan J, Yang G-S, Fu ZR et al. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: A multi-center experience in Shanghai, China. J Cancer Res Clin Oncol 2009;135:1403-1412.
15. Yau T, Chan P, Epstein R et al. Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 2009;29:10-17.
16. Lai CL, Wu PC, Chan GC et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988;62:479-483.
17. Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: Two ends of the therapeutic spectrum. Lancet Oncol 2004;5:409-418.
18. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
19. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
20. Summary of product characteristics: Eloxatin. Available at http://www.sanofi-aventis.co.uk/products/Eloxatin_SPC.pdf. Accessed May 27,2011.
21. Raymond E, Chaney SG, Taamma A et al. Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 1998;9:1053-1071.
22. Boige V, Raoul JL, Pignon JP et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 2007;97:862-867.
23. Louafi S, Boige V, Ducreux M et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): Results of a phase II study. Cancer 2007;109:1384-1390.
24. Qin SK, Chao MR, Qian J et al. Treatment of advanced primary liver cancer patients with FOLFOX4 regimen containing oxaliplatin. Chin Clin Oncol 2005;10:58-60.
25. Qin SK, Wang YJ, Wu Q. et al. Preliminary results of a phase II trial of FOLFOX4 regimen in Chinese patients with unresectable primary liver cancer. J Clin Oncol 2006;24:629s, 14065a.
26. Yen Y, Lim DW, Chung V. et al. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: A California Cancer Consortium Trial. Am J Clin Oncol 2008;31:317-322.
27. Qin S, Bai Y, Lim HY et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013;31:3501-3508.
28. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute ofthe United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
29. O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35: 549-556.
30. Ohkubo K, Kato Y, Ichikawa T. et al. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer 2002; 94:2663-2668.
31. Zhou Y, Si X, Wu L et al. Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: A meta-analysis of observational studies. World J Surg Oncol 2011;9:108.
32. Goldberg RM, Tabah-Fisch I, Bleiberg H et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085-4091.
33. Kochi M, Ichikawa W Meguro E et al. Phase II study of FOLFOX4 with “wait and go” strategy as first-line treatment for metastatic colorectal cancer. Cancer Chemother Pharmacol 2011;68:1215-1222.
34. Abou-Alfa GK, Johnson P, Knox JJ et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: A randomized trial. JAMA 2010;304:2154-2160.
35. Yeo W, Mok TS, Zee B et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532-1538.
36. Zhai B, Sun XY. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 2013;5:345-352.
37. Mao K, Zhang J, He C et al. Restoration of miR-193b sensitizes hepatitis B virus-associated hepatocellular carcinoma to sorafenib. Cancer Lett 2014 [E-pub ahead of print].
38. Cheng A, Kang Y, Lin D et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2011; 29(suppl):4000a.
39. Johnson PJ, Qin S, Park JW. et al. Brivanibversus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study. J Clin Oncol 2013;31:3517-3524.
40. Park JW, Finn RS, Kim JS et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011;17:1973-1983.
41. Llovet JM, Decaens T, Raoul JL et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenibfailed: Results from therandomized phase III BRISK-PS study. J Clin Oncol 2013;31:3509-3516.
42. Toh H, Chen P, Carr B et al. A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis. J Clin Oncol 2009;27(suppl):4581a.
43. Alberts SR, Fitch TR, Kim GP et al. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: A phase II North Central Cancer Treatment Group Clinical Trial. Am J Clin Oncol 2012;35: 329-333.
44. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-442.
45. Lopez PM, Villanueva A, Llovet JM. Systematic review: Evidence-based management of hepatocellular carcinoma—an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006; 23:1535-1547.
46. Simonetti RG, Liberati A, Angiolini C et al. Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials. Ann Oncol 1997;8:117-136.
47. Zhu AX. New agents on the horizon in hepato-cellularcarcinoma. Ther AdvMed Oncol 2013;5:41-50.
48. Wu Q, Qin SK. Features and treatment options of Chinese hepatocellular carcinoma. Chin Clin Oncol 2013;2:38-43.
49. Yang LQ, Qin SK, Zhao NL et al. Clinical study of FOLFOX4 regimen as systemic chemotherapy for advanced primary liver carcinoma. Chin Clin Oncol 2013;18:108-113.
50. Yang CX, Qin SK. Clinical study progression of oxaliplatin for advanced primary hepatic carcinoma. Chin Clin Oncol 2010;15:845-855.
51. Assenat E, Boige V, Thezenas S et al. Sorafenib (S) alone versus S combined with gemcitabine and oxaliplatin (GEMOX) in first-line treatment of advanced hepatocellular carcinoma (HCC): Final analysis of the randomized phase II GONEXT trial (UNICANCER/FFCD PRODIGE 10 trial). J Clin Oncol 2013;31(suppl):4028a.
52. Zaanan A, Williet N, Hebbar M et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: A large multicenter AGEO study. J Hepatol 2013;58:81-88.